OBI Is Awarded ABEA 2026 “Best ADC Developer in Taiwan”
CEO Heidi Wang Receives Women’s Leadership in ADC Development Award
2026.Mar.03
News
OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships
2025.Dec.19
News
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
2025.Dec.18
News
OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation
2025.Dec.05
News
OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma
2025.Nov.16
News
OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.
2025.Sep.26
News
OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025
2025.Sep.03
News
OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC
2025.Aug.31
News
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
2025.Jul.22
News
OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025
GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs
2025.Jun.10
News
OBI Pharma Showcases Next-Generation ADC Development at 2025 World ADC Asia Summit
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
2025.Mar.12
News
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation
Events
Scientific
ADC Asia Congress 2026
2026.Mar.11 ~ 2026.Mar.12
Sands Expo & Convention Centre, Singapore
Event Time2026.Mar.11 ~ 2026.Mar.12
Event LocationSands Expo & Convention Centre, Singapore
